IL-10 Knockout Colitis Model
logo

IL-10 Knockout Colitis Model

IL-10 knockout mice spontaneously develop chronic enterocolitis due to uncontrolled immune responses against commensal gut microbiota. Ace Therapeutics provides customized B6-IL-10 KO mice to help clients test new prophylactic and therapeutic agents for IBD.

Accelerate Your IBD Research with Our IL-10 Knockout Colitis Model

A Spontaneous and Chronic IBD Model

The IL-10 KO mouse is a spontaneous model of colitis that closely mirrors the chronic nature and immunological complexity of human IBD.

Colitis typically develops 3-4 months after weaning, depending on genetic background and microbial environment, allowing researchers to study disease onset and progression in a naturalistic setting.

What You'll Learn in the Case Study

Download our detailed case study to explore:

  • The timeline of spontaneous disease development and phenotype evolution across age groups
  • Quantitative data on body weight, DAI, colon and lymphoid organ changes
  • How the IL-10 KO model supports extended therapeutic intervention windows and long-term efficacy testing

Comprehensive Readouts and Analytical Capabilities

  • Body weight and disease activity index (DAI) score
  • Mesenteric lymph node (mLN) and spleen weight (normalized to body weight)
  • Colon weight and macroscopic pathology
  • Histological evaluation of mucosal architecture and immune infiltration
  • Cytokine profiling (e.g., TNF-α, IFN-γ, IL-6, IL-17, IL-1β)

Download the case study to see how our IL-10 knockout colitis model can accelerate your preclinical IBD research and therapeutic development.